Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cleaved caspases and p-H2AX expression were detected by western blot in HCT116 cells (E) and HT29 cells (F). The cells were co-cultured with F. nucleatum or treated with CQ, and different concentrations of Oxaliplatin and 5-FU.

    Cell, 2017, 170(3):548-563.e16. Oxaliplatin purchased from Selleck.

    Immunocytochemical staining of SW620 (metastatic) cells after treatment with 10 uM oxaliplatin (F) or 10 uM ginsenosides 20(S)-Rg 3 (G) and negative staining (H). Cells demonstrated differential expression of histone H4.

    J Proteomics 2014 10.1016/j.jprot.2014.10.009. Oxaliplatin purchased from Selleck.

  • PDT and oxaliplatin combination treatment. A) Bar graph showing response (total volume of residual viale nodules normalized to no treatment control) to PDT treatmen (2.5 J/cm2), oxaliplatin treatment (10 μM), and PDT followed by oxaliplatin at the same doses. The dramatic enhancement, beyond the additive effect of the two modalities independently suggests there may be a synergistic interaction. B) A representative region from a culture stained with calcein AM and ethidium bromide following treatment with the PDT + oxaliplatin combination shows relatively small pockets of viable disease and many dead relative to untreated cultures.

    Optical Methods for Tumor Treatment and Detection 2013 10.1117/12.2010730. Oxaliplatin purchased from Selleck.

     

    Growth inhibitory effects of Oxaliplatin in human pancreatic cancer cells. MiaPaCa-2 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (1% FBS) containing DMSO (control) or indicated doses of Oxaliplatin (Selleckchem). Cell viability 72 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. 

    2013 Dr. Edita Aksamitiene from Thomas Jefferson University. Oxaliplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 MnXIR5l1d3SxeHnjbZR6KEG|c3H5 MkXENQKBmzF4MNMg{txO M1zUU|Q5yqCq NVrF[XpWUUN3ME21MljDqMLzwrCwMlUh|ryP MnTxNlY1PzR4OUO=
CaES-17 MofvR5l1d3SxeHnjbZR6KEG|c3H5 NF;NVG8x6oDVMU[wxsDPxE1? NHnoR401QMLiaB?= M3TIPGlEPTB;NT61xsDDucLiMD6yJO69VQ>? Mn3SNlY1PzR4OUO=
SW480 NX;R[mJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPmOFghcMLi NHzaXodKSzVyPUGuPFch|ryP NWXNe|N6OjZ{Nkm3OVk>
HCT116 MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[wTVI1QCCqwrC= NY[5fXllUUN3ME2xNU45PiEQvF2= MoTQNlYzPjl5NUm=
LoVo M1qyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXrOFghcMLi NW[wV2plUUN3ME25OE45OyEQvF2= MmnNNlYzPjl5NUm=
SK-BR-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[xTZNKSzVyPUOxMlAhyrFiMD6xJO69VQ>? NGHBO2gzPjJzMUW5NS=>
MCF-7 NHP4emRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XjXmlEPTB;MUWuOEDDuSByLkOg{txO NX6yXlk2OjZ{MUG1PVE>
MDA-MB-231 M1S3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;XcGNPUUN3ME2yN{4yKMLzIECuNUDPxE1? M{nrd|I3OjFzNUmx
HCT116 p53+/+ MWTGeY5kfGmxbjDBd5NigQ>? NYDSdGlEOS93IN88US=> MnL0NlQwPDhiaB?= M4PIWYlv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= M1S0XFI3OjB6NUKz
LoVo  MXrGeY5kfGmxbjDBd5NigQ>? M2HOVFEwPSEQvF2= NHTLZ4QzPC92ODDo NVXMcodKcW6mdXPld{B1emGwc3PybZB1cW:wYXygdoVxemW|c3nvckBw\iCGVWStUi=> M{XPSlI3OjB6NUKz
SNU-398 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjTWYJKSzVyPU[uOeKhyrIEoEGuNUDPxE1? NXjjZXZiOjZzNkC0Nlk>
Hep-G2 NEDXRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPWdIpkUUN3ME2xN{4yyqEEsdMgNU43KM7:TR?= M37Q[|I3OTZyNEK5
SNU-475 NVzGN2F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fDWGlEPTExvK6zNEDPxE1? MXiyOlE3ODR{OR?=
SNU-387 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\CS|lxUUN3ME2yOeKhyrIEoEKuO{DPxE1? NXPMOm5LOjZzNkC0Nlk>
HT29 NEGzTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXqTWM2OD1yLki4xsDDucLiMD6yJO69VQ>? M4[xTFI3OTR6NUm2
HCT116 NFzWTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;te2xFUUN3ME2wMlQyyqEEsdMgNE4xOiEQvF2= M1:2dlI3OTR6NUm2
PA-1 MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3T4TVAuOjBizszN MUGyOE81QCCq NUHIeGdscW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Mon2NlYyOzh4N{G=
OVCAR-5 NWrFU|VxS2WubDDWbYFjcWyrdImgRZN{[Xl? MlTvNE03OCEQvF2= NUHKT2tTOjRxNEivO|IhcA>? NYjqbIFPcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MYSyOlE{QDZ5MR?=
SK-OV-3 NVzqSWpmS2WubDDWbYFjcWyrdImgRZN{[Xl? NYTCN4gxOC1zMECg{txO MVmyOE81QC95MjDo NWDCcmZbcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MmLLNlYyOzh4N{G=
PA-1 MlnESpVv[3Srb36gRZN{[Xl? MWexNEDPxE4EoB?= MYmyOIg> MnfkeJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz NHruUIgzPjF|OE[3NS=>
OVCAR-5 MnuzSpVv[3Srb36gRZN{[Xl? M{Oy[lMxKM7:TR?= MnfGOFhp MmT3eJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz MmLSNlYyOzh4N{G=
SK-OV-3 NXPJdFkyTnWwY4Tpc44hSXO|YYm= Mk\xOVAh|ryP NUDWSWd6QTZiaB?= MUD0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO= NFHx[JMzPjF|OE[3NS=>
PA-1 Mn3ISpVv[3Srb36gRZN{[Xl? MYmxNEDPxE4EoB?= MoPSOFhp NYLve2J[fXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| MnLKNlYyOzh4N{G=
OVCAR-5 MVHGeY5kfGmxbjDBd5NigQ>? M4\vUVMxKM7:TR?= MVe0PIg> NH3XZ|Z2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? NHjBUWMzPjF|OE[3NS=>
SK-OV-3 NFzLRpdHfW6ldHnvckBCe3OjeR?= Ml:xOVAh|ryP MkW2PVYhcA>? Mnf5eZAuemWpdXzheIV{KHSqZTDzeJJme3NibHnnZY5leyCob4KgUmsh[2WubD3hZ5RqfmG2aX7nJJJm[2WydH;yd{BidmRiVGLBTWwhemWlZYD0c5J{ NGrBbIUzPjF|OE[3NS=>
PA-1 NFS0[|FHfW6ldHnvckBCe3OjeR?= M1OxflExKM7:TdMg MX6yOIg> M4nTV5Bzd22xdHXzJJNmdnOrdHn2bZR6KG:oIH;2ZZJq[W5iY3HyZ4lvd22jIITvJG5MKGOnbHytcYVlcWG2ZXSgZ5l1d2y7c3nz MkL6NlYyOzh4N{G=
OVCAR-5 NEPGdmRHfW6ldHnvckBCe3OjeR?= NFHYV2kzOCEQvF5CpC=> MonKNlRp MYnwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= NXfCbGlxOjZzM{i2O|E>
SK-OV-3 M4fQ[GZ2dmO2aX;uJGF{e2G7 Ml\JOVAh|ryPwrC= NFfpe2c1QCCqwrC= NUXGU4FreHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> Ml\6NlYyOzh4N{G=
CT26  NY\YVJUxTnWwY4Tpc44hSXO|YYm= MmXCOEBuVQ>? M4DKSFQ5KGkEoB?= NYP3WplNcW6mdXPld{BifXSxcHjh[5k> M4m4VlI3OTN5MEGy
CT26  MYLGeY5kfGmxbjDBd5NigQ>? NUnuVnpyPCCvTR?= NGrhe5c1QCCqwrC= NGX2TG5qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wy|IH;mJIF2fG:yaHHnfU1z\WyjdHXkJJBzd3SnaX7zMEB{fWOqIHHzJGxEOy2LSTygRoVkdGmwMTDhcoQhSVSJNR?= M123TVI3OTN5MEGy
CT26  NY\peJc1S2WubDDWbYFjcWyrdImgRZN{[Xl? NVfRTmV3PCCvTR?= MWG0PEBpyqB? NEfGSnhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeI8hPTNwMjW= Mn;VNlYyOzdyMUK=
BE NH7ITI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HIeWlEPTB;Mz6zN{DPxE1? MkTsNlYxOjNyOEW=
Colo205 NGX3OYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXNXVBZUUN3ME2zMlM{KM7:TR?= MXqyOlAzOzB6NR?=
DLD1 NHXn[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInGTnJKSzVyPUKuNFEh|ryP NVS1OlZOOjZyMkOwPFU>
HT29 M{G5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPud2xKSzVyPUKuOlkh|ryP NUDnXFZ1OjZyMkOwPFU>
HCT15 NIHlVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXwSlhKSzVyPUGuOFMh|ryP M2r1WFI3ODJ|MEi1
HCT116 NVvHNI1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nEWmlEPTB;MT6wOEDPxE1? M3uxTFI3ODJ|MEi1
HCT116p53- M4\STWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HKTmlEPTB;MT6wPEDPxE1? NYf1VIxOOjZyMkOwPFU>
KM12 NVvhbJF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDxbYhKSzVyPUSuN|ch|ryP MmnBNlYxOjNyOEW=
LoVo NEHKdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPxelVMUUN3ME2xMlIh|ryP MnvtNlYxOjNyOEW=
RKO MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\UT3ByUUN3ME2xMlI{KM7:TR?= Mn3SNlYxOjNyOEW=
SW480 NFX0R|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\vNZNKSzVyPUKuPFYh|ryP NH3hZ4UzPjB{M{C4OS=>
SW620 Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HxZmlEPTB;Mz62PEDPxE1? MYCyOlAzOzB6NR?=
MC38 MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnGTWM2OD1{MzFOwG0hyrFiMh?= NVfNOVZYOjZyMESwPFQ>
HT29 M4j4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\r[2lEPTB;NkOg{txOKMLzIEG4 NULvc4VYOjZyMESwPFQ>
DLD-1 NFjxO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrKTWM2OD1|Mj6yJO69VQ>? MoPONlYxODNyOEW=
HT-29 M3S4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTN3Lk[g{txO MXKyOlAxOzB6NR?=
SiHa MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zvS2lEPTB;MD64JOKyKDBwMTFOwG0> NE\lXmEzPThyMUCwOy=>
S3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP5R5FKSzVyPUWzMlUhyrFiMT61JO69VQ>? NGDZb40zPThyMUCwOy=>
AGS MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rw[WlEPTB;MUCuOkDPxE1? M1zEVlI2Pzh7MEW3
MKN-45 NUHudVBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzWUoNzUUN3ME2xOE4xKM7:TR?= NYG2fmJvOjV5OEmwOVc>
TMK-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;wTWM2OD1{Mj62JO69VQ>? MoO4NlU4QDlyNUe=
SCM-1 NY[zbYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS4cZVSUUN3ME2xO{42KM7:TR?= NVvF[IFsOjV5OEmwOVc>
HCT-15 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT0WIdKSzVyPUiuOlQh|ryP MlPQNlU4PjF2N{m=
DiFi NGW3cpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn1NHJKSzVyPUGwMlk2KM7:TR?= NXS4[3c1OjV5NkG0O|k>
DLD-1 Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\mfVhvUUN3ME24MlY2KM7:TR?= NXK2SngyOjV5NkG0O|k>
COLO-320DM NEHOcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPlN5hKSzVyPUWuN|gh|ryP M2PHe|I2PzZzNEe5
SNU-175 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFwNUGg{txO M2fjcVI2PzZzNEe5
HT-29 NYfkV5Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDrTWM2OD13LkKyJO69VQ>? NV7s[o1oOjV5NkG0O|k>
SW620 NX;k[YV6TnWwY4Tpc44hSXO|YYm= MVqxNQKBkcL3Zz;tcC=> NEDyUYUzPOLCiXi= M4\4Oolv[3KnYYPld{BNSzNvSVmgZYNkfW23bHH0bY9vKGGwZDDk[YNz\WG|ZYOgVFYzKGW6cILld5Nqd25? NF\6XZYzPTd2OUSyNC=>
SW480 Mn3VSpVv[3Srb36gRZN{[Xl? Ml[5NVDjiIoEtXevcYw> NVXLeVlxOjUkgJno M1WzNolv[3KnYYPld{BNSzNvSVmgZYNkfW23bHH0bY9vKGGwZDDk[YNz\WG|ZYOgVFYzKGW6cILld5Nqd25? MXKyOVc1QTR{MB?=
SW620 M13mR2Z2dmO2aX;uJGF{e2G7 M2KxZVEx6oDLwsXnM41t MlHHNlTjiImq NUHpWph7\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4 MWmyOVc1QTR{MB?=
SW480 NYf0cG5pTnWwY4Tpc44hSXO|YYm= Mn24NVDjiIoEtXevcYw> MWqyOQKBkWh? MmfJ[Y5p[W6lZYOgZ4VtdHWuYYKgZZV1d3CqYXfpZ{BndHW6 MY[yOVc1QTR{MB?=
A549 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH4R3Y6UUN3ME21MlghyrFiMD62JO69VQ>? M2fU[VI2PjJ3MkSz
A549/CDDP NGKwWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\IeGN{UUN3ME2xPE43KMLzIEGuNkDPxE1? NXj4XXg2OjV4MkWyOFM>
Panc-1 NXXaVZVFS2WubDDWbYFjcWyrdImgRZN{[Xl? Mnj1NlUwPTBizszN NEGyT|AzPC92ODDo NIfrVItqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? NWftc21GOjV2NES5NVQ>
MIAPaCa-2 NV;k[G9RS2WubDDWbYFjcWyrdImgRZN{[Xl? MlTuNlUwPTBizszN NFvkdVMzPC92ODDo NWDpS5pYcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD NHe4RYMzPTR2NEmxOC=>
SW1990 NH23ZpFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFrwNoczPS93MDFOwG0> M{\wPVI1NzR6IHi= NVjlT4JjcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD MkjaNlU1PDR7MUS=
HPDE NYfnZY5IS2WubDDWbYFjcWyrdImgRZN{[Xl? MkXCNlUwPTBizszN NEjFcGUzPC92ODDo MYXpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> MorwNlU1PDR7MUS=
Panc-1 NUDFbo56SXCxcITvd4l{KEG|c3H5 NFLpWnAzPeLCidM1US=> M{jqWFI1KGh? NYrCbGZ7cW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= NEfqZmkzPTR2NEmxOC=>
MIAPaCa-2 MWPBdI9xfG:|aYOgRZN{[Xl? M33wblI26oDLwsXN MYmyOEBp NVzCfGYzcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= MYGyOVQ1PDlzNB?=
Panc-1 NGPGTZJHfW6ldHnvckBCe3OjeR?= NXK1R5RNOjYkgJpCuW0> M2H4fVI1NzR6IHi= NXqxNJM1cW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zxsA> M3;JfFI2PDR2OUG0
MIAPaCa-2 M1;2UWZ2dmO2aX;uJGF{e2G7 NYLVZXgzOjYkgJpCuW0> M1zoeVI1NzR6IHi= MVfpcoR2[2W|IHPs[YF3[WenIH;mJHBCWlBuIHPhd5Bie2VvOTygZ4F{eGG|ZT24JIFv\CClYYPwZZNmNTQEoB?= NYDhco0yOjV2NES5NVQ>
SW480 NYjIbVBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\5O|IhcMLi M1PwdGlEPTB;MUCuO:KyOi5{NjFCuYcwdUx? M3\y[|I2OzZyNkOx
HCT116  NInxOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PYfFczKGkEoB?= NXPoNHlEUUN3ME22MlI{yrFyLke1JOK2\y:vTB?= NWnwT2s3OjV|NkC2N|E>
COC1 MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\tTWM2OD12Nj6yNOKhyrIEoEOuNVQh|ryP M1q0WVI2OzB5NES4
SGC7901 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVruS2VEUUN3ME2yNU44O8LiwsJCpFMvODhizszN NELwdXUzPTNyN{S0PC=>
A549 NELE[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PmXWlEPTB;NUGuNFjDqMLzwrCxNE46PiEQvF2= MofpNlU{ODd2NEi=
HepG2 M4W4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrhTWM2OD1zND6yOOKhyrIEoEGuPFIh|ryP M2Dt[VI2OzB5NES4
MCF-7 Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF2LkK0xsDDucLiMT64NkDPxE1? MVOyOVMxPzR2OB?=
HCT-116 M1LKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\pTWM2OD14LkK0xsDDucLiMj65O{DPxE1? NHK5VZYzPTNyN{S0PC=>
HT-29 NXXO[mpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLUTWM2OD53MDFOwG0> NVrnWG9ROjV|MEe0OFg>
HEK293 M3XUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjKUXk4UUN3ME24MlgzyqEEsdMgOU42QSEQvF2= MUSyOVMxPzR2OB?=
HUVEC NWrmcXRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFzLkOwxsDDucLiMT6wNkDPxE1? MYqyOVMxPzR2OB?=
SW480 M{\neGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C5cVHDqM7:TR?= NX3uUHBGOC15MjDo NULQRW5ocW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? Mnn5NlQ6QTd2NUG=
HT-29 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHFWnYyyqEQvF2= M2HlelAuPzJiaB?= NGO0WmZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? NWPlSGF1OjR7OUe0OVE>
HCT116 NX\2T4x2TnWwY4Tpc44hSXO|YYm= NEW1[WQzNzViwsXN MkTJNlQwPDhiaB?= M2rRT5N2eHC{ZYPz[ZMhe3W{dnn2bY4hdVKQQTDlfJBz\XO|aX;u MYiyOFc3OTRzMR?=
SW480  M2jaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe0PEBpyqB? M1HnRWlEPTB;MkCuPEB2\y:vTB?= Mni5NlQ4OjB4N{W=
SW620 M{LOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP5OIpmOTBvN{CgcYcwVA>? NU\BNWRGOjRxNEivO|IhcA>? NWHCPW96cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MonpNlQ3PDZ|MEW=
Caco2  MlzSSpVv[3Srb36gRZN{[Xl? M4\kNFMxyqEQvF2= NHTtU4YzPCCq MV\EUXNQ MUfpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFjPMVEtKEGNUkHDMEBidmRiTmHPNS=> Ml3YNlQ2PTZ2MUW=
Caco2  M13CW2Z2dmO2aX;uJGF{e2G7 NEL6eYg{NzFyL{OwJO69VQ>? NXLNRndYOTZiaB?= MnTTSG1UVw>? NGXXcIhqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCDS2KxR|EtKE6TT{GsJGhQNTFuIF3SVFItyqCjbnTNVnA{yqCmb4PlMYRmeGWwZHXueIx6 Mo\YNlQ2PTZ2MUW=
Caco2 Mmj3SpVv[3Srb36gRZN{[Xl? M{PlVVMxNzFyMNMg{txO Mo\PNVbDqGh? NU\FRm4zTE2VTx?= MUDhZ5RqfmG2ZYOgUpJnOg>? MnXaNlQ2PTZ2MUW=

... Click to View More Cell Line Experimental Data

In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Formulation: Water solution
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents to the product individually and in order:
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
Synonyms L-OHP

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01928290 Recruiting Stomach Neoplasms|Esophageal Neoplasms Washington University School of Medicine November 8, 2013 Phase 2
NCT03050814 Not yet recruiting Colorectal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 2017 Phase 2
NCT02997228 Not yet recruiting Colorectal Adenocarcinoma|High-Frequency Microsatellite Instability|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) November 2017 Phase 3
NCT02912559 Not yet recruiting Colon Adenocarcinoma|DNA Repair Disorder|Lynch Syndrome|Microsatellite Instability|Stage IIIA Colon Cancer|Stage IIIB Colon Cancer|Stage IIIC Colon Cancer National Cancer Institute (NCI) September 2017 Phase 3
NCT03043729 Not yet recruiting Rectal Cancer|Rectosigmoid Cancer AIO-Studien-gGmbH|Institut für Klinisch-Onkologische Forschung (IKF) Frankfurt|Sanofi February 2017 Phase 2
NCT03000374 Not yet recruiting Rectal Cancer Grupo Espanol Multidisciplinario del Cancer Digestivo|Pivotal S.L.|Amgen February 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID